Spyre Therapeutics, Inc. (SYRE) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Spyre Therapeutics, Inc. · SYRE · NASDAQ · Healthcare · Biotechnology
Spyre Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing novel therapeutics for inflammatory bowel disease (IBD). Their pipeline includes monoclonal antibody candidates targeting key IBD pathways, currently in preclinical development.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. · Price as of Sep 10, 2026
MoonshotScore v2 · Spyre Therapeutics (SYRE)
WeakWhy this rating? Method, drivers & history
A strong balance sheet, but bottom-tier quality and weak growth; the market is already moving on it.
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but bottom-tier quality and weak growth; the market is already moving on it.
- $0 revenue
- beat 5 of 8
- Altman Z 62.25 · Piotroski F 2
Holding back: weak fundamentals
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 29 | Weak | |
| 29 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 29 | Weak |
The score moved from 24 to 29 (+5); the largest pillar moves were Momentum -26 and Valuation -5.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Last close | $88.22 | |
| Change on the day | +1.49% | |
| 52-week range | $14.51 – $110.17 | |
| Market capitalisation | $7.66B | |
| Shares traded on the day | 544K |
Price & events
Council Score · weighted blend of 3 available disciplines
Split View
39/100 · DSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
9-Factor Breakdown
Growth Potential
Legends Council
6 available lenses
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Munger's Mindset
Balance Sheet & Valuation
Read on: Sep 9, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Cache read when this page was built: Sep 11, 2026.
Watch the SYRE film — every key number, told as a short cinematic story
~2 min · open the film
What is Spyre Therapeutics (SYRE), and what does it report?
Short answer · as of
Spyre Therapeutics, Inc. (SYRE) is listed on NASDAQ and classified as Healthcare / Biotechnology. It is based in Waltham, US, employs 125 people and is led by Cameron Turtle. In Q2 FY2026 it reported revenue of $0 and net income of -$36M. The market values it at $7.66B.
What do the latest results show for Spyre Therapeutics (SYRE)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0. Against analyst estimates the company has beat 5 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$36M | -$0.43 |
| Q1 FY2026 | $0 | -$69M | -$0.88 |
| Q4 FY2025 | $90M | -$63M | -$0.83 |
| Q3 FY2025 | $0 | -$11M | -$0.19 |
What are the financial strengths and risks for Spyre Therapeutics (SYRE)?
Short answer · as of
On the numbers, what is working is balance-sheet strength, positive momentum. What is holding it back is weak fundamentals. The distress and quality screens read Altman Z 62.25 · Piotroski F 2. Trailing ratios: ROE -24.3% · ROA -15.3% · current ratio 18.53 · earnings yield -2.4% · free-cash-flow yield -2.8%.
Data-derived red flags
- Negative return on equity (-24.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $429.7M recently.
What should you watch next at Spyre Therapeutics (SYRE)?
Short answer · as of
Published price targets run $49.00–$130.00 · consensus $106.58 against a quoted price of $88.22 (as of Sep 10, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Spyre Therapeutics compare with its peers?
Short answer · as of
Spyre Therapeutics's comparison group includes 15 peers with published MoonshotScores. The table ranks the 12 highest-scoring peers; these are company scores, not expected investment returns.
| Company | Price | Market value | Score |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | $345.55 | $10.2B | 98 |
| Eli Lilly and Company (LLY) | $1122.21 | $1.06T | 96 |
| Liquidia Corporation (LQDA) | $67.71 | $6.02B | 96 |
| Ligand Pharmaceuticals Incorporated (LGND) | $289.25 | $5.80B | 95 |
| Bio-Techne Corporation (TECH) | $72.35 | $11.3B | 93 |
| Bristol-Myers Squibb Company (BMY) | $63.34 | $129B | 90 |
| Caris Life Sciences, Inc. (CAI) | $24.04 | $6.80B | 82 |
| Belite Bio, Inc. (BLTE) | $175.07 | $7.02B | 80 |
| ACADIA Pharmaceuticals Inc. (ACAD) | $27.74 | $4.75B | 80 |
| Protagonist Therapeutics, Inc. (PTGX) | $146.75 | $9.44B | 77 |
| AbbVie Inc. (ABBV) | $254.98 | $451B | 76 |
| Apogee Therapeutics, Inc. (APGE) | $135.07 | $8.36B | 72 |
| Spyre Therapeutics (SYRE) ranks here | |||
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $49.00 – $130.00
- Consensus target
- $106.58
- Median target
- $115.50
Measured against a quoted price of $88.22 (as of Sep 10, 2026).
Insider activity
SEC Form 4 · Last 180 days
- Transactions
- 100
- Insiders
- 10
- Purchases
- 21
- Sales
- 79
What has been published about Spyre Therapeutics (SYRE)?
- Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target
- Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
- BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target
What Investors Ask About Spyre Therapeutics (SYRE) — Healthcare
These answers are editorial: 1 of these 9 answers is drawn from the SYRE research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for SYRE?
SYRE carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Spyre Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing novel therapeutics for inflammatory bowel disease (IBD).
Is SYRE a good stock?
Stock Expert AI does not rate SYRE buy, sell or hold. Spyre Therapeutics, Inc. carries a MoonshotScore on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for SYRE?
The main risks for Spyre Therapeutics include the inherent uncertainties of clinical development, as clinical trial failures could significantly impact the company's valuation.
What are the key factors to evaluate for SYRE?
Spyre Therapeutics, Inc. (SYRE) holds a MoonshotScore in the low range. Analysts target $106.58 (+21%). Focus on inflammatory bowel disease (IBD), a market with significant unmet needs. Not financial advice.
How frequently does SYRE data refresh on this page?
SYRE's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SYRE's recent stock price performance?
Spyre Therapeutics, Inc. (SYRE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel pipeline of monoclonal antibody candidates. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SYRE overvalued or undervalued right now?
Spyre Therapeutics, Inc. (SYRE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $106.58 (+21%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of SYRE?
Yes, most major brokerages offer fractional shares of Spyre Therapeutics, Inc. (SYRE) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SYRE's earnings and financial reports?
Spyre Therapeutics, Inc. (SYRE) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SYRE earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Sources — where every figure on this page comes from (23 dated figures)
The 23 rows below are exactly the facts the dated sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Every figure in those sections is stored with the date it is true for and the source it came from, and derived figures restate their arithmetic. The quarterly income statement is reprinted as filed under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 1-9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. Where a cached provider read carries no stamp of its own, the as-of is this page's own content date and the source column says so.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
own.insiders | Insider transactions (SEC Form 4) | 100 transactions · 21 buys, 79 sells · 10 insiders · last 180 days | OFFICIAL | SEC Form 4 filings, carried by FMP |
FMP — 20 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Last close | $88.22 | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | +$1.29 | FMP | Financial Modeling Prep (FMP) · quote | |
px.change | Change on the day | +1.49% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $7.66B | FMP | Financial Modeling Prep (FMP) · profile | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history | Reported versus estimated, recent quarters | beat 5 of 8 | FMP | Financial Modeling Prep (FMP) · earnings history | |
fin.scores | Distress and quality screens | Altman Z 62.25 · Piotroski F 2 | FMP | Financial Modeling Prep (FMP) · financial scores — cached provider read, as carried by this page | |
px.range52 | 52-week range | $14.51 – $110.17 | FMP | Financial Modeling Prep (FMP) · profile — cached provider read, as carried by this page | |
px.volume | Shares traded on the day | 544K | FMP | Financial Modeling Prep (FMP) · quote | |
id.sector | Sector / industry (FMP taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) · profile taxonomy | |
id.hq | Headquarters | Waltham, US | FMP | Financial Modeling Prep (FMP) · company profile — cached provider read, as carried by this page | |
id.employees | Employees | 125 | FMP | Financial Modeling Prep (FMP) · company profile | |
id.ceo | Chief executive | Cameron Turtle | FMP | Financial Modeling Prep (FMP) · key executives | |
fin.q_income | Net income, Q2 FY2026 | -$36M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -24.3% · ROA -15.3% · current ratio 18.53 · earnings yield -2.4% · free-cash-flow yield -2.8% | FMP | Financial Modeling Prep (FMP) · key metrics TTM — cached provider read, as carried by this page | |
earn.pt | Analyst price targets in force | $49.00–$130.00 · consensus $106.58 | FMP | Financial Modeling Prep (FMP) · price-target consensus | |
earn.pt_range | Analyst price target, low to high | $49.00 – $130.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus | |
earn.pt_consensus | Consensus analyst price target | $106.58 | FMP | Financial Modeling Prep (FMP) · price-target consensus | |
earn.pt_median | Median analyst price target | $115.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 26 of 100 · Weak · pillars 24 / 78 / 44 / 39 / 95 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 24 → 29 (+5) | OURS | Stock Expert AI score snapshots |
- Published
- Methodology
- How the MoonshotScore is computed
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.